Publisert 24.03.2020

Regenics AS secures loan from Innovation Norway

Regenics AS secures loan facility from Innovation Norway

While Regenics are posting surplus in their books and has secured public funding for 2020 to 2023, from EU, Regenics AS has secured a minor loan facility from Innovation Norway to be kept as rescue cash in the wake of the Covid-19 situation.

It is expected that SMEs may be supported by financial arrangements due to the Covid-19 crisis. Regenics is by the loan apporval from Innjovation Norway presumed to be eligible is such support initiatiatives fro innovative R&D based SMEs, should they move towards realization.

 For more info, please contact Henrik Lund at henrik.lund@regenics.no or mobile +47 90971219

 

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.